Mobile Site ›

What the FDA Relabeling of Abacavir Means for You and Your Patient

If HSR Symptoms are Present4

Slide 15

November 2008

Now for patients who are about to receive abacavir, this is a suggested algorithm for approaching the prob. First one must determine is HLA-B*5701 testing is available. If it is not avail or if the clinician has no access to test, then provider should review risk factors with patient and start abacavir therapy and monitor for the occurrence of hypersensitivity reaction looking for signs and symptoms consistent with syndrome.

However, if testing is available, then the status of this allele should be determined with lab testing. If negative, the provider should proceed with initiating abacavir therapy. If the allele is present, then abacavir therapy should be avoided.

If HSR Symptoms are Present4


Jump to section: